Abstract
Background: Hepatitis B virus (HBV) reactivation may occur with chemotherapy and/or immunotherapy. Antiviral prophylaxis is recommended for all patients who are hepatitis B surface antigen (HBsAg)-positive during chemotherapy and/or immunosuppressive therapy. However, the optimal timing of antiviral therapy before chemotherapy and/or immunosuppressive therapy is not fully elucidated.
Patients and methods: We retrospectively evaluated 446 HBsAg-positive patients who underwent chemotherapy and/or immunosuppressive therapy. The cumulative rates of HBV reactivation were evaluated using the Kaplan-Meier method and were compared using the log-rank test. The risk factors of HBV reactivation were examined via univariate and multivariate analyses using the Cox proportional hazards model.
Results: The cumulative HBV reactivation rates of patients who received antiviral therapy before chemotherapy and/or immunosuppressive therapy were significantly lower than those of patients who received antiviral therapy after chemotherapy and/or immunosuppressive therapy (P = 0.002). The incidence of HBV reactivation was significantly different between patients who received antiviral therapy at least 1 day before chemotherapy and/or immunosuppressive therapy and those who did not (P = 0.006). No significant difference was observed in the HBV reactivation rates between patients who received antiviral therapy at least 2 days (P = 0.310), 3 days (P = 0.494), and 1 week (P = 0.655) before chemotherapy and/or immunosuppressive therapy and those who did not. The multivariate Cox proportional hazards model showed that women had a lower risk of developing HBV reactivation than men (P = 0.025). The use of the prophylactic antiviral agent entecavir, compared with lamivudine and telbivudine, was associated with the decreased risk of developing HBV reactivation (P = 0.002).
Conclusion: HBsAg-positive patients who received preemptive antiviral therapy after chemotherapy and/or immunosuppressive therapy had a high risk of developing HBV reactivation. However, it is not necessary for patients to receive antiviral therapy at least 1 week before chemotherapy and/or immunosuppressive therapy.
Keywords: antiviral prophylaxis, hepatitis B surface antigen (HBsAg)-positive, hepatitis B virus reactivation, risk factors, chemotherapy and/or immunosuppressive therapy
Introduction
Hepatitis B virus (HBV) infection is prevalent worldwide 1,2. Chemotherapy and immunosuppressive therapy may reactivate such infection, with possible fatal outcomes 3. Approximately 40% of patients who are hepatitis B surface antigen (HBsAg)- positive and received chemotherapy developed HBV reactivation; among these patients, 13% and 16% are at risk of liver failure and mortality 4, respectively. Based on cautious prospective serological testing, liver damage due to HBV reactivation is a two-stage process. Initially, during intense cytotoxic or immunosuppressive therapy, a remarkedly enhanced viral replication is observed, as reflected by increases in the serum levels of HBV DNA, hepatitis B e-antigen (HBeAg), and HBV DNA polymerase, resulting in the widespread infection of hepatocytes. Due to the withdrawal of cytotoxic or immunosuppressive therapy, immune function will be restored; then, there will be a rapid immune-mediated destruction of HBV- infected hepatocytes. This destruction can manifest as hepatitis, hepatic failure, and even death 5-7.
Because hepatitis is related to HBV virological reactivation, the Centers for Disease Control and Prevention, American Association for the Study of Liver Diseases, Asian Pacific Association for the Study of the Liver, European Association for the Study of the Liver, and American Gastroenterological Association endorsed a policy involving screening for HBsAg and hepatitis B core antibody (anti-HBc) levels in patients undergoing chemotherapy or immunosuppressive therapy 2,8-11. Prophylactic antiviral therapy is recommended for all patients who are HBsAg-positive and for selected patients who are HBsAg-negative and anti-HBc-positive who receive B-cell-depleting agents or other highly aggressive chemotherapy. Therapy must be continued at least 6-12 months after the discontinuation of chemotherapy and immunosuppressive therapy. However, to date, there is no available consensus on the optimal time to initiate prophylactic antiviral agents in these conditions. Some randomized clinical trials have shown that antiviral therapy administered at least 1 week or at the start of chemotherapy or immunosuppressive therapy is more effective than deferred treatment after reactivation is diagnosed using frequent HBV DNA monitoring 2. But there is no study has shown how long to take antiviral agents in advance was preferable (one day or one week?). The intake of prophylactic antiviral agents at least 1 week before chemotherapy or immunosuppressive therapy may result in a delay of antitumor therapy and may produce additional medical costs.
Thus, we aimed to retrospectively compare the efficacy of antiviral prophylaxis before and after chemotherapy and/or immunosuppressive therapy to prevent HBV reactivation and to confirm the optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B virus during chemotherapy and/or immunosuppressive therapy.
Patients and Methods
Inclusion and exclusion criteria
The records of patients with HBV infection who received chemotherapy and/or immunosuppressive therapy between January 2014 and February 2018 in Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University in southern China were screened for eligibility. The inclusion criteria were as follows: a) patients aged ≥16 years, b) with HBsAg-positive status upon diagnosis, and c) receiving at least one cycle of chemotherapy and/or immunosuppressive therapy. The exclusion criteria were as follows: a) patients with hepatitis A, C, D, and E virus infection or HIV infection, b) with decompensated liver disease, such as a history of ascites, variceal hemorrhage, hepatic encephalopathy, or serum total bilirubin >2.0 mg/dL before chemotherapy or immunosuppressive therapy, and c) with hepatocellular carcinoma.
The institutional review board of Meizhou People's Hospital approved the study, and a written informed consent was obtained from all patients.
Definition of HBV reactivation
HBV reactivation was defined as follows: HBV DNA level ≥20,000 IU/mL with no baseline HBV DNA, newly detected HBV DNA level ≥100 IU/mL with previously stable or undetectable levels, elevated HBV DNA ≥2 log10 with detectable HBV DNA at baseline, and reverse seroconversion to HBsAg- positive status 2,12.
Characteristics of the patients and follow-up
The following variables were assessed: age; sex; clinical characteristics, including diagnosis of a hematologic or solid tumor; and initiation time of prophylactic antiviral and antiviral agents. Biochemical liver function tests including glutamic- pyruvic transaminase (ALT), glutamic-oxalacetic transaminase (AST), bilirubin, and albumin levels as well as HBV DNA levels were checked at baseline, at the start of every new cycle of chemotherapy and/or immunosuppressive therapy. After the completion of therapy, biochemical liver function and HBV-DNA levels were checked every 4-12 weeks. Tests for serum HBsAg, hepatitis B surface antibody (anti-HBs), HBeAg, anti-HBc status, and hepatitis B e-antibody (anti-HBe) were usually done at baseline. The follow up data was collected from January 2014 and September 2018.
Statistical analysis
χ2 or Fisher's exact test was used to assess the relationship between HBV reactivation and clinicopathological features. Continuous variables without a normal distribution were compared using the Mann-Whitney U-test. The risk factors of HBV reactivation were examined via univariate and multivariate analyses using the Cox proportional hazards model. The cumulative rates of HBV reactivation were evaluated using the Kaplan-Meier method and compared using log-rank tests. A P value <0.05 for all two-tailed tests were considered statistically significant. All statistical analyses were carried out using the Statistical Package for the Social Sciences software version 19.0 (SPSS Inc., Chicago, Illinois, the USA).
Results
Characteristics of the patients
We identified 446 patients with resolved HBV infection who received chemotherapy or immunosuppressive therapy in the analysis. The characteristics of the patients are shown in detail in Table 1. Of the 446 patients, 239 (53.6%) were men. The median age of the participants was 52 (interquartile range [IQR]: 44-59) years. Most patients (n=391; 87.6%;) had solid tumors, and 12.4% (n=55) presented with hematological malignancies, such as leukemia or lymphoma. Among the patients with solid tumors, the most prevalent cancer site was the gastrointestinal tract (n=153; 34.3%). Seventeen (3.9%) and 75 (16.8%) patients received rituximab-based treatment regimens and anthracycline, respectively.
Table 1.
Clinical characteristics of the study participants (n=446)
| Clinical characteristics | n (%) |
|---|---|
| Sex ratio (male: female) | 239 (53.6):207 (46.4) |
| Age, [median (IQR)] (years) | 52 (44-59) |
| Tumor type | |
| Solid tumors | 391 (87.6) |
| Breast cancer, n (%) | 80 (17.9) |
| Gastrointestinal cancer, n (%) | 153 (34.3) |
| Head and neck cancer, n (%) | 56 (12.5) |
| Lung cancer, n (%) | 49 (11.0) |
| Genitourinary cancer, n (%) | 41 (9.2) |
| Other cancers, n (%) | 12 (2.7) |
| Hematological malignancies | 55 (12.4) |
| Lymphomas, n (%) | 40 (9.0) |
| Leukemia, n (%) | 15 (3.4) |
| Chemotherapy regimen | |
| Anthracycline-containing | 75 (16.8) |
| Steroid-containing | 5 (1.1) |
| Rituximab-containing | 0 (0.0) |
| Combined regimen with steroids and anthracycline | 25 (5.6) |
| Combined regimen with steroids, anthracycline, and rituximab | 17 (3.9) |
| Combined regimen with steroid and rituximab | 0 (0.0) |
| Other chemotherapy regimen | 324 (72.6) |
| Duration of antiviral prophylaxis before chemotherapy (days) | |
| Median (range) | 1 (-1-2) |
| Pretreatment (baseline) biochemistry | |
| Baseline ALT (U/L) | 26 (18-43) |
| ≥50 U/L | 91 (20.4) |
| <50 U/L | 355 (79.6) |
| Baseline HBV DNA (IU/mL) | |
| ≥2,000 IU/mL | 231 (51.8) |
| <2,000 IU/mL | 215 (48.2) |
| Baseline HBV DNA (IU/mL) | |
| ≥100 IU/mL | 355 (79.6) |
| <100 IU/mL | 91 (20.4) |
| Baseline ALT ≥50 U/L and HBV DNA ≥2000 IU/mL, n (%) | 50 (11.2%) |
| HBeAg status | |
| Positive | 36 (8.1) |
| Negative | 410 (91.9) |
| HB-PreS1-Ag status | |
| Positive | 231 (51.8) |
| Negative | 215 (48.2) |
| Prophylactic antiviral regimen, n (%) | |
| Lamivudine | 117 (26.2) |
| Entecavir | 304 (68.2) |
| Adefovir | 0 |
| Telbivudine | 25 (5.6) |
| Tenofovir | 0 |
| Duration of follow-up [median (IQR)] (months) | 8 (4.5-13) |
Continuous variables expressed as median (range).
ALT, alanine aminotransaminase (normal range 13-50 U/L); anti-HBe, hepatitis B e- antibody; HBeAg, hepatitis B e-antigen; HB-PreS1-Ag, hepatitis B virus PreS1-Ag; HBV, hepatitis B virus; IQR, interquartile range.
In terms of viral factors, 215 (48.2%) and 91 (20.4%) patients had baseline HBV DNA levels <2,000 IU/mL and <100 IU/mL, respectively, and 36 (8.1%) patients were positive for HBeAg. Most patients were treated with entecavir (ETV) (n=304; 68.2%), lamivudine (LAM) (n=117; 26.2%), or telbivudine (LDT) (n=25; 5.6%) for HBV prophylaxis. The median duration of antiviral prophylaxis before chemotherapy or immunosuppressive therapy was 1 (IQR: -1-2) day. The median duration of follow-up was 8 (IQR: 4.5-13) months. Among these patients, 52 (11.6%) were diagnosed with HBV reactivation during or after chemotherapy and/ or immunosuppressive therapy courses.
Comparison of HBV reactivation rates between the groups according to time of treatment initiation (before or after chemotherapy and/or immunosuppressive therapy)
We divided the patients into two groups according to the time when antiviral therapy was provided (before or after chemotherapy and/or immunosuppressive therapy). The HBV reactivation analysis showed that the cumulative HBV reactivation rates of patients who received antiviral therapy before chemotherapy and/or immunosuppressive therapy was significantly lower than those of patients who received antiviral therapy after chemotherapy and/or immunosuppressive therapy, as determined using the log-rank test (P = 0.002, Fig. 1A). Furthermore, those who received antiviral therapy more than 1 week after chemotherapy or immunosuppressive therapy had a significantly higher risk of HBV reactivation (P <0.001, Fig. 1B).
Figure 1.
(A) Comparison of the cumulative HBV reactivation rates between the groups who received antiviral therapy before and after chemotherapy and/or immunosuppressive therapy. (B) Comparison of the cumulative HBV reactivation rates between the groups according to the time when the patients received antiviral therapy (more than or less than 1 week after chemotherapy and/or immunosuppressive therapy). Che., chemotherapy and/or immunosuppressive therapy.
Comparison of HBV reactivation rates between the groups according to the different durations of antiviral therapy before chemotherapy and/or immunosuppressive therapy
The patients were divided into two groups according to the different durations of antiviral prophylaxis before chemotherapy and/or immunosuppressive therapy. The incidence of HBV reactivation was significantly different between the patients who received antiviral therapy at least 1 day before chemotherapy or immunosuppressive therapy, and patients who received antiviral therapy less than 1 day before chemotherapy or immunosuppressive therapy (P = 0.006, Fig. 2A). However, no significant difference was observed in the HBV reactivation rates between the two groups (at least 2 days before or less than 2 days before, P = 0.310; at least 3 days before or less than 3 days before, P = 0.494; and at least 1 week before or less than 1 week before, P = 0.655) (Figs. 2B, C, D).
Figure 2.
Comparison of the cumulative HBV reactivation rates between the groups according to the different durations of antiviral therapy before chemotherapy and/or immunosuppressive therapy: (A) at least 1 day or less than 1 day before chemotherapy and/or immunosuppressive therapy, (B) at least 2 days or less than 2 days before chemotherapy and/or immunosuppressive therapy, (C) at least 3 days or less than 3 days before chemotherapy and/or immunosuppressive therapy, and (D) at least 1 week or less than 1 week before chemotherapy and/or immunosuppressive therapy. Che., chemotherapy and/or immunosuppressive therapy.
Clinicopathological characteristics associated with HBV reactivation
A total of 52 patients developed HBV reactivation (the reactivation group), whereas 394 patients did not (the non-reactivation group). The clinical characteristics of these two groups are summarized in Table 2. The correlation analysis revealed a significant inverse correlation between the development of HBV reactivation as well as sex (male, P = 0.016), HBV DNA level ≥100 IU/mL (P = 0.048), hematological malignancies (P = 0.012), use of the prophylactic antiviral regimen LAM (P = 0.014), and administration of anti-viral prophylaxis after chemotherapy (P = 0.015). No statistically significant difference was observed in terms of age, baseline liver function (ALT level and HBeAg status), and chemotherapy regimens between the two groups. In addition, the cumulative HBV reactivation rates in men and those who used LAM were significantly higher than those of women and those who used ETV and LDT (P = 0.021 and P = 0.013, respectively, based on log-rank test; Figs. 3A, D). However, no significant difference was observed in the cumulative HBV reactivation rates between the groups with solid tumors and hematological malignancies and between the groups treated with rituximab and those who were not (P = 0.068 and P = 0.192, respectively, based on log-rank test; Figs. 3B, C).
Table 2.
Characteristics of patients with and without hepatitis B virus (HBV) reactivation
| Characteristic | Patients without HBV reactivation (n =394) % | Patients with HBV reactivation (n =52) % | P-value |
|---|---|---|---|
| Sex | 0.016 | ||
| Male | 203 (84.9) | 36 (15.1) | |
| Female | 191 (92.3) | 16 (7.7) | |
| Age (years) | 53 (44-59) | 49 (41-57) | 0.106 |
| ALT (U/L) | 26 (18-44) | 29 (21-43) | 0.384 |
| Elevated ALT | 0.611 | ||
| Yes | 79 (86.8) | 12 (13.2) | |
| No | 315 (88.7) | 40 (11.3) | |
| HBV DNA ≥2,000 (IU/mL) | 0.984 | ||
| Yes | 204 (88.3) | 27 (11.7) | |
| No | 190 (88.4) | 25 (11.6) | |
| HBV DNA <100 (IU/mL) | 0.048 | ||
| Yes | 75 (82.4) | 16 (17.6) | |
| No | 319 (89.9) | 36 (10.1) | |
| HBeAg | 0.212 | ||
| Positive | 29 (89.0) | 7 (11.0) | |
| Negative | 365 (88.3) | 45 (11.7) | |
| Tumor type | 0.012 | ||
| Solid tumors | 351 (89.8) | 40 (10.2) | |
| Hematological malignancies | 43 (78.2) | 12 (21.8) | |
| Chemotherapy regimen | 0.242 | ||
| Rituximab-containing | 13 (76.5) | 4 (23.5) | |
| Without rituximab | 381 (88.8) | 48 (11.2) | |
| Prophylactic antiviral regimen | 0.014 | ||
| Lamivudine | 95 (81.2) | 22 (11.8) | |
| Entecavir | 278 (91.4) | 26 (8.6) | |
| Telbivudine | 21 (84.0) | 4 (16.0) | |
| Antiviral prophylaxis | 0.015 | ||
| Before chemotherapy | 278 (90.8) | 28 (9.2) | |
| After chemotherapy | 116 (82.9) | 24 (17.1) | |
| Antiviral prophylaxis | 0.513 | ||
| More than 1 week before chemotherapy | 48 (85.7) | 8 (14.3) | |
| One week or less before chemotherapy | 346 (88.7) | 44 (11.3) | |
ALT, alanine aminotransaminase (normal range 13-50 U/L); HBeAg, hepatitis B e-antigen.
Figure 3.
(A) Comparison of the cumulative HBV reactivation rates according to sex. (B) Comparison of the cumulative HBV reactivation rates according to different tumor types. (C) Comparison of the cumulative HBV reactivation rates according to the risk factors associated with rituximab-based chemotherapy or other types of treatment. (D) Comparison of the cumulative HBV reactivation rates according to different prophylactic antiviral regimens. Che., chemotherapy and/or immunosuppressive therapy.
Using the covariates listed in Table 3, the multivariate Cox proportional hazards model showed that men were more significantly at risk of HBV reactivation than women (HR = 0.502; 95% confidence interval (CI) = 0.276-0.915, P = 0.025). ETV, not LAM and LDT, was associated with a decreased risk of HBV reactivation (HR = 0.417; 95% CI = 0.238-0.731, P = 0.002). The administration of anti-viral prophylaxis less than 1 day before chemotherapy or immunosuppressive therapy was associated with an increased risk of HBV reactivation, as compared to at least 1 day before chemotherapy or immunosuppressive therapy (HR = 2.366; 95% CI = 1.354-4.136, P = 0.003) (Table 3).
Table 3.
Univariate and multivariate analyses of risk factors for HBV reactivation
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Sex | 0.513 (0.285-0.926) | 0.027 | 0.502 (0.276-0.915) | 0.025 |
| Age | 0.995 (0.973-1.018) | 0.688 | ||
| Elevated ALT | 1.069 (0.559-2.044) | 0.840 | ||
| HBV DNA <100 (IU/mL) | 0.545 (0.302-0.986) | 0.045 | 0.682 (0.374-1.245) | 0.213 |
| HBeAg | 1.347 (0.605-2.998) | 0.466 | ||
| Tumor type | 1.788 (0.936-3.416) | 0.079 | 1.938 (0.989-3.795) | 0.054 |
| Rituximab- containing | 1.925 (0.692-5.356) | 0.210 | ||
| Prophylactic antiviral regimen | 0.457 (0.265-0.790) | 0.005 | 0.417 (0.238-0.731) | 0.002 |
| Antiviral prophylaxis | 2.265 (1.311-3.915) | 0.003 | 2.366 (1.354-4.136) | 0.003 |
ALT, alanine aminotransaminase (normal range 13-50 U/L); HBeAg, hepatitis B e- antigen; HR, hazard ratio.
Discussion
HBV reactivation during cytotoxic chemotherapy is an important issue in clinical settings in countries, such as China, where chronic HBV infection is endemic. HBsAg-positive patients are at high risk of HBV reactivation particularly if their HBV DNA levels are elevated 13,14, and these patients should receive anti-HBV prophylaxis prior to the initiation of immunosuppressive or cytotoxic therapy, which is supported by three randomized controlled trials of HBsAg- and anti-HBc-positive patients receiving anticancer therapy 15-17. The optimal time for the initiation of antiviral prophylaxis remains uncertain. However, when such treatment is initiated only after major biochemical abnormalities are observed, the results are not entirely satisfactory. This may not be effective in reducing liver injury 18,19 because the immunologic events causing the flare have already been activated, and viral elimination is ongoing 7. Our study addressed the question whether preemptive therapy should be initiated prior or during the initiation of chemotherapy or deferred after chemotherapy. This study showed that HBsAg-positive patients are at high risk of HBV reactivation when preemptive antiviral therapy is deferred as well as previous studies 20.
Regardless of baseline serum HBV DNA levels, antiviral prophylaxis should be administered to patients with chronic hepatitis B (CHB) before the onset of anticancer therapy or a finite course of chemotherapy or immunosuppressive therapy 21. Based on the literature, antiviral agents are provided 7 days prior to treatment. To date, no studies have assessed about the initiation of antivirals before chemotherapy and/or immunosuppressive therapy. Our study showed that the incidence of HBV reactivation was significantly different between the two groups (at least 1 day before or not) (P = 0.006, Fig. 2A). However, no significant difference was observed in the HBV reactivation rates between the two groups (at least 2 days before or not, P = 0.310; at least 3 days before or not, P = 0.494; and at least 1 week before or not, P = 0.655). This may mean antiviral treatment is should be provided 1 day prior to the start of chemotherapy and/or immunosuppressive therapy, but not necessary provided 1 week prior to the start of chemotherapy and/or immunosuppressive therapy. There is no need to delay chemotherapy and/or immunosuppressive therapy administered to HBsAg-positive patients, which may lead to disease progression in order to antiviral treatment 1 week in advance.
Several risk factors for HBV reactivation in patients with cancer have been identified. According to previous studies, those with detectable or high levels of serum HBV DNA prior to the start of immunosuppressive therapy have a higher risk of HBV reactivation than those with undetectable or low levels of HBV DNA 13,14,22. In our study, a significantly lower rate of HBV reactivation was observed in patients with HBV DNA levels <100 IU/mL compared with those with HBV DNA levels ≥ 100 IU/mL. Male sex has been the most consistent host factor that is associated with an increased risk of HBV reactivation 23,24. In a study of 78 HBsAg-positive patients with various cancer types, a higher reactivation rate was observed in men than in women (29% vs 10%) 24. Our study showed that men had a higher risk of developing HBV reactivation. LAM is a nucleoside analog with potent antiviral activity against HBV and is a safe, well-tolerated, and inexpensive drug. Moreover, it is the first-line antiviral agent for the prophylaxis of HBV reactivation in patients receiving chemotherapy or immunosuppressive therapy. However, its long-term use results in drug resistance 25. Other antiviral drugs, such as ETV or tenofovir, are frequently used as alternatives to the first-line therapy for chronic hepatitis B due to the lower risk of resistance 26. A previous study has compared the prophylactic effect of LAM and ETV in patients with diffuse large B-cell lymphoma who were receiving rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, and the result of such study showed that ETV was beneficial 27. In our study, a higher rate of HBV reactivation was observed in patients who used LAM as antiviral prophylaxis. Therefore, the possible relationship between HBV reactivation and the initiation time of antiviral prophylaxis in patients undergoing intense chemotherapy and/or immunotherapy must be further assessed. The present study had limitations. That is, only a short-term retrospective chart review was conducted.
Conclusion
HBsAg-positive patients who received preemptive antiviral therapy after chemotherapy and/or immunotherapy had a high risk of developing HBV reactivation. However, it is not necessary for patients to receive antiviral therapy at least 1 week before chemotherapy. In the future, prospective studies with large sample size must be conducted to validate the optimal timing as well as the clinical and economic benefits of using antiviral prophylaxis in patients who are HBsAg-positive and are treated with chemotherapy and/or immunotherapy.
Acknowledgments
The authors would like to thank Yuxiang Liu, Min Ye, Chunling Wen, Shihua Gao and Wentong, Zou for the data acquisition. We would like to thank Peng Wang (Sun yat-sen memorial hospital, Sun yat-sen university) for proofreading the manuscript. We would like to thank all of the participants in this study. This work was supported by grants from the National Natural Science Foundation of China (No. 81402560) and the Guangdong Province Science and Technology Plan Project (No. 2017A020215029).
Author Contributions
Xiaofang Zou and Guowu Wu contributed equally to this work. Guowu Wu contributed to study concept and design, obtained funding, and study supervision. Xiaofang Zou contributed to write the article and statistical analysis. Longhua Guo contributed to analysis and interpretation of data. Yinfang Gu, Zhijun Yang, Ping Huang and Tianhuang Liu contributed to acquisition of data. Jingjing Zhao and Guowu Wu contributed to critical revision of the article for important intellectual content. All authors read and approved the final manuscript.
Abbreviations
- ALT
glutamic-pyruvic transaminase
- AST
glutamic-oxalacetic transaminase
- anti-HBs
hepatitis B surface antibody
- anti-HBe
hepatitis B e-antibody
- anti-HBc
hepatitis B core antibody
- CHB
chronic hepatitis B
- ETV
entecavir
- HBV
Hepatitis B virus
- HBsAg
hepatitis B surface antigen
- HBeAg
hepatitis B e-antigen
- HB-PreS1-Ag
hepatitis B virus PreS1-Ag
- HR
hazard ratio
- IQR
interquartile range
- LAM
lamivudine
- LDT
telbivudine
- R-CHOP
rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone
References
- 1.Paul S, Saxena A, Terrin N. et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Annals of internal medicine. 2016;164(1):30–40. doi: 10.7326/M15-1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221–244. doi: 10.1053/j.gastro.2014.10.038. e223. [DOI] [PubMed] [Google Scholar]
- 3.Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. Journal of gastroenterology and hepatology. 2013;28(1):31–37. doi: 10.1111/j.1440-1746.2012.07280.x. [DOI] [PubMed] [Google Scholar]
- 4.Loomba R, Rowley A, Wesley R. et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Annals of Internal Medicine. 2008;148(7):519–528. doi: 10.7326/0003-4819-148-7-200804010-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Luo X, Au W, Liang R. et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy—pathogenesis and management. Reviews in medical virology. 2001;11(5):287–299. doi: 10.1002/rmv.322. [DOI] [PubMed] [Google Scholar]
- 6.Hoofnagle JH, Dusheiko GM, Schafer DF. et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Annals of Internal Medicine. 1982;96(4):447–449. doi: 10.7326/0003-4819-96-4-447. [DOI] [PubMed] [Google Scholar]
- 7.Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120(4):1009–1022. doi: 10.1053/gast.2001.22461. [DOI] [PubMed] [Google Scholar]
- 8.Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology. 2009;49(S5):S35–S44. doi: 10.1002/hep.22882. [DOI] [PubMed] [Google Scholar]
- 9.Sarin SK, Kumar M, Lau GK. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology international. 2016;10(1):1–98. doi: 10.1007/s12072-015-9675-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. Jama. 2015;313(16):1617–1618. doi: 10.1001/jama.2015.2571. [DOI] [PubMed] [Google Scholar]
- 11.Reddy KR, Beavers KL, Hammond SP. et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–219. doi: 10.1053/j.gastro.2014.10.039. quiz e216-217. [DOI] [PubMed] [Google Scholar]
- 12.Gonzalez SA, Perrillo RP. Reactivation of Hepatitis B Virus Due to Cancer Chemotherapy and Other Immunosuppressive Drug Therapy. Hepatitis B Virus in Human Diseases: Springer. 2016. pp. 399–431. [DOI] [PMC free article] [PubMed]
- 13.Yeo W, Zee B, Zhong S. et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. British Journal of Cancer. 2004;90(7):1306–1311. doi: 10.1038/sj.bjc.6601699. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Lau GK, Leung Y, Fong DY. et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99(7):2324–2330. doi: 10.1182/blood.v99.7.2324. [DOI] [PubMed] [Google Scholar]
- 15.Jang JW, Choi JY, Bae SH. et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43(2):233–240. doi: 10.1002/hep.21024. [DOI] [PubMed] [Google Scholar]
- 16.Lau GK, Yiu HH, Fong DY. et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742–1749. doi: 10.1053/j.gastro.2003.09.026. [DOI] [PubMed] [Google Scholar]
- 17.Hsu C, Hsiung CA, Su IJ. et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008;47(3):844–853. doi: 10.1002/hep.22106. [DOI] [PubMed] [Google Scholar]
- 18.Yeo W, Steinberg JL, Tam JS. et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. Journal of medical virology. 1999;59(3):263–269. doi: 10.1002/(sici)1096-9071(199911)59:3<263::aid-jmv1>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
- 19.Liao CA, Lee CM, Wu HC. et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. British journal of haematology. 2002;116(1):166–169. doi: 10.1046/j.1365-2141.2002.03239.x. [DOI] [PubMed] [Google Scholar]
- 20.Lau GK, Yiu HH, Fong DY. et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742–1749. doi: 10.1053/j.gastro.2003.09.026. [DOI] [PubMed] [Google Scholar]
- 21.Zhang M, Zhu G, Shi K. et al. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos (t) ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016;7(21):30642–30658. doi: 10.18632/oncotarget.8907. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zhong S, Yeo W, Schroder C. et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. Journal of viral hepatitis. 2004;11(1):55–59. doi: 10.1046/j.1352-0504.2003.00467.x. [DOI] [PubMed] [Google Scholar]
- 23.Lok AS, Liang RH, Chiu EK. et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology. 1991;100(1):182–188. doi: 10.1016/0016-5085(91)90599-g. [DOI] [PubMed] [Google Scholar]
- 24.Yeo W, Chan PK, Zhong S. et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. Journal of medical virology. 2000;62(3):299–307. doi: 10.1002/1096-9071(200011)62:3<299::aid-jmv1>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
- 25.Di Bisceglie AM, Lok AS, Martin P. et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61(2):703–711. doi: 10.1002/hep.27609. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Lok AS, McMahon BJ, Brown Jr RS. et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284–306. doi: 10.1002/hep.28280. [DOI] [PubMed] [Google Scholar]
- 27.Huang H, Li X, Zhu J. et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. Jama. 2014;312(23):2521–2530. doi: 10.1001/jama.2014.15704. [DOI] [PubMed] [Google Scholar]